Amoxycillin-Safe-Fish-Antibiotics

Develops, manufactures and markets ringworm oral antibiotics list generic drugs and innovative branded pharmaceuticals for specialty markets. Adjusting for these items, income from continuing operations for the full year ended would have been $55.1 million, or $1.59 per diluted share. Generic RD expense decreased $8.0 million due to lower internal development costs, lower performance incentive compensation of $4 million, and the non-recurrence of one-time costs associated with a third party development agreement.

Selling, General and Administrative

Selling, general and administrative (SGA) expense of $137.9 million for the year ended decreased slightly from $138.2 million in 2007. To the extent any statements made in this news release contain information that is not historical, these statements antibiotic for chlamydia from are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially drug store  from those expressed herein.

Par invites investors and the general public to listen to a webcast of the conference call. Par reported a loss for the fourth quarter ended of $32.0 million, or $0.96 per share.

Revenues from Strativa represented 15.1% of total revenues, as compared to 11.0% in 2007. These benefits were tempered by $19.2 million of costs related to business development activities in support aldara vipps of Strativa Pharmaceuticals, Par's branded division, a $6.0 million loss on an investment, $1.6 million of severance costs. Research and development (RD) expenses decreased 23.2% from the year ended, to $59.7 million, and represented 10.3% of total revenues.

This is compared with reported net income antibiotics generic lopid  and mcg of $49.9 amoxycillin million, or $1.43 per share in 2007. By comparison, fourth quarter 2007 results included a pre-tax gain of $3.1 million from Par's sale of its remaining investment in Optimer Pharmaceutical, Inc. Revenues for the fourth quarter 2008 increased 4.0% compared with the same period in 2007 due primarily to the launch of sumatriptan succinate injection, increased sales of metoprolol and Megace(R) ES. "This momentum should continue into 2009 as the results of our restructuring takes hold and solid product sales continue."

In October, Par announced its amoxicillin plans to resize aciclovir  its generic division by significantly reducing its research and development expense and trimming its product portfolio resulting in a workforce reduction of approximately 190.

Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results

WOODCLIFF LAKE, N.J., / - / -- Par Pharmaceutical Companies, Inc. Adjusting for these items and other special items, income from continuing operations for the fourth quarter 2008 would have been $7.1 azithromycin tablets and alcohol tablet million, or $0.21 per diluted share. Fourth quarter 2008 reported, or GAAP, loss from continuing operations also included the write-off of a restructuring charge of $15.4 million and other related costs of $3.8 million, $49.2 million in charges due to an unfavorable court decision and related legal fees, $5.3 million gain on non-core ANDA sales and the sale of other product rights, $4.9 million impairment charge related to various investments, and a $7.9 million gain related to nealson debt extinguishment.

Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended, in other of the Company's filings with the SEC from time to time, including Current Reports on long term storage of antibiotics Form 8-K, and on general industry and economic conditions. "Given the challenging environment of 2008, we are pleased with the operating results over the last two quarters," stated Carter G.

For the full year 2008, Par reported a loss of $47.8 million, or $1.43 per share. amoxicillin and potassium clavulanate of one-time Strativa milestone payments.

Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company natural antibiotics for a toothache assumes no obligation to update any forward-looking statements. This is compared with reported revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share, for 2007. metoprolol succinate For the year ended, Par reported total revenues of $578.1 million and a loss from continuing operations of $45.9 million, or $1.38 per share.

For the year ended total revenue decreased antibiotics 24.9% to $578 million compared with the same period a year earlier as a result of a decrease in the number of new product launches, trimming of Par's generic product portfolio, increased competition in Par's antibiotics to for upper respiratory generic products. Adjusting for these items and the fourth quarter special items, income from continuing operations for the full year ended would have been $1.8 million, or $0.05 per diluted share. Revenues from Par's generic segment declined 28.3% for the full year 2008 to $491.1 million primarily due to competitive pressures that adversely affected the volume and pricing of certain existing safe fish antibiotics products. Strativa revenues increased 2.7% from the prior year to $87.1 million driven by a mid-year price increase, fees related to the co-promotion of Androgel(R), and timing of trade buying patterns offset by a more challenging reimbursement environment.

Products which experienced significant volume and pricing declines included fluticasone, propranolol, cabergoline, various amoxicillin products, ranitidine syrup, tramadol HCl and acetaminophen tablets driven by Par's exit from the market, and lower royalty payments of ondansetron tablets, among others. For the fourth quarter ended, Par reported total revenues of $161.3 million and a loss from continuing operations of $30.5 million, or $0.91 per zithromax to treat pilonidal cyst share. Strativa's gross margin increased to 77.7% of branded revenues from 76.0% in 2007 due to revenue growth discussed above.

The decrease in SGA expense was primarily due to lower employee compensation, the non-recurrence of the 2007 stock option tender offer and the resulting lower stock option costs, and lower expenses relates to sales and marketing of Megace(R) ES, which offset higher legal fees, severance costs and increased outside consulting costs. Safe Harbor Statement

antibiotic for dogs skin dog Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. A replay of the conference call will be available commencing approximately one hour after the call. By comparison, and in addition to the fourth quarter 2007 events cited above, reported GAAP income from continuing operations for the full year 2007 included a $20.0 million gain on the sale to Optimer of marketing rights to the investigational drug Difimicin (Par 101), a $4.5 million investment gain on the sale of shares of Optimer com stock, and net settlement gains of $0.6 million. For and other company amoxicillin and potassium clavulanate information, visit.

As of, Par ear antibiotics had working capital of $193.8 million, which includes $142 million of current liabilities due to mature in September 2010. Par's 2008 gross margin represented 30.5% of total revenues, a decrease from 34.9% in 2007. Par's reported, or GAAP, loss from continuing operations for the year ended, included the write-off of an intangible asset and certain inventories related to the trimming of its generic product portfolio of $5.5 million, a charge related to a government pricing contingency of $4.8 million, a $7.8 million net impairment charge related to various investments, $7.5 million in development milestone payments to MonoSol Rx and Alfacell, and $9.0 million of gains from the sale of non-core ANDAs and other product rights.

The dial-in number is 888-679-8034 for domestic callers and 617-213-4847 for international callers.

This is compared with reported revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share, for the same period in 2007. Generic product gross margin decreased to 22.2%